Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2017 07:00 ET | Source: Cyclacel

Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting

BERKELEY HEIGHTS, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) "Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
November 09, 2017 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
November 02, 2017 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
November 01, 2017 09:02 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting

BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
September 21, 2017 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using...
September 08, 2017 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

BERKELEY HEIGHTS, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using...
August 09, 2017 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a clinical-stage biopharmaceutical company using...
August 07, 2017 07:00 ET | Source: Cyclacel

Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression

BERKELEY HEIGHTS, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
August 02, 2017 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
July 21, 2017 14:00 ET | Source: Cyclacel

Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle,...